GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Are Stem Cell Therapy Side Effects?

Stem cell therapy side effects vary by treatment. Blood stem cell transplants can cause nausea, vomiting, fatigue, mouth sores, hair loss, low blood counts, infection, and bleeding. Donor transplants can also cause graft-versus-host disease; possible long-term problems include infertility, organ damage, and secondary cancers. Many early problems come from the chemotherapy or radiation given before the transplant. Stem cell transplant Unapproved regenerative products carry different, less predictable risks: the FDA has received reports of blindness, tumors, and life-threatening infections. These reports do not establish how often each harm occurs. Important patient and consumer information about regenerative medicine therapies

A blood transplant, an approved mesenchymal stromal cell product, and an experimental knee injection do not share one safety profile. Before comparing a hospital program with a private clinic offer, identify the exact product, cell source, dose, route, and condition being treated. The sections below separate these treatments rather than giving a misleading single risk percentage.

What Are Stem Cell Therapy Side Effects?

Why there is no single side-effect list

Blood-forming stem cells restore blood-cell production after transplant conditioning. They are different from mesenchymal stromal cells, or MSCs, used in certain cell products. “Stem cell therapy” is therefore not a specific product name or an approval category. Stem cell transplant

An intravenous infusion and an injection into a joint involve different procedures and risks. Safety depends on how the cells are collected, processed, and given, as well as the patient’s health. Using your own cells does not remove contamination or administration risks. Important patient and consumer information about regenerative medicine therapies

  • The procedure: needle sticks, anesthesia, surgery, bleeding, or infection where cells are collected or injected.
  • The preparation: strong chemotherapy or radiation before a blood transplant.
  • The cells: immune reactions, graft-versus-host disease, or tissue growing where it should not.
  • The product: contamination, poor processing, or a reaction to preservatives and other ingredients.
  • The follow-up: an infection treated too late or a complication that gets missed.

A side effect is an unwanted treatment effect. An adverse event is a medical problem recorded during or after treatment; its timing alone does not prove the treatment caused it. This distinction matters when reading safety reports from people who were already seriously ill.

For blood transplants, conditioning treatment explains many early effects, including low blood counts, infection risk, and fatigue. Graft-versus-host disease instead involves donor immune cells attacking the recipient’s tissues. Stem cell transplant

Common side effects

During or shortly after an infusion

Infusion reactions depend on the product and its ingredients. Ryoncil, an FDA-approved MSC product for a specific transplant complication, can cause hypersensitivity reactions, including anaphylaxis. Its label lists fever, breathing difficulty, and low blood pressure as possible signs during or after infusion. The treating team should interrupt the infusion if a reaction occurs and assess the patient promptly. Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display

Ryoncil’s trial safety percentages cover adverse reactions collected up to 100 days following treatment; they are not rates of immediate infusion reactions. The children had steroid-refractory acute graft-versus-host disease after a donor transplant. Their results cannot predict the risk of a clinic-sold “wellness” infusion. FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display

Do not assume fever or flu-like symptoms mean the treatment is working. Symptoms need assessment, not reassurance based on a presumed treatment response.

After a blood stem cell transplant

The National Cancer Institute lists nausea, vomiting, fatigue, loss of appetite, mouth sores, hair loss, and skin reactions as short-term problems. The strong pre-treatment can also lower blood counts, which raises the risk of infection and bleeding. Stem cell transplant

That fatigue can make everyday tasks difficult. Mouth sores can make eating and drinking painful, and poor intake can lead to dehydration. Tell the transplant team early if you cannot eat or drink.

Normal blood counts do not mean your immune system has fully recovered. The NCI describes full immune recovery as taking several months after an autologous transplant using your own cells, and 1 to 2 years after an allogeneic donor or syngeneic identical-twin transplant. Individual recovery varies. Stem cell transplant

After a joint injection

Local pain or swelling can follow a joint injection, but there is no reliable universal frequency or recovery time for the varied products sold as stem cell injections. Infection inside the joint, called septic arthritis, is a risk of invasive joint procedures. A hot, increasingly swollen, severely painful knee needs urgent assessment. CD013342_what are benefits and risks stem cell injections knee osteoarthritis

The 2025 Cochrane review included 25 trials with 1,341 participants and searched evidence through 15 September 2023. It rated evidence for pain and function as low certainty, but evidence for serious harms as very low certainty. Few reported serious events cannot establish that an injection is safe. CD013342_what are benefits and risks stem cell injections knee osteoarthritis

The review did not establish cartilage regrowth or slower disease progression. Less pain is not proof that damaged cartilage has regenerated. CD013342_what are benefits and risks stem cell injections knee osteoarthritis

After a clinic-sold “stem cell” infusion

No trusted list of “usual” side effects exists for this group. The products vary, and reporting has large gaps. The US Food and Drug Administration (FDA) has received reports of blindness, tumor growth, nerve-related events, life-threatening bacterial infections, and immune reactions after unapproved regenerative products. These reports provide no rate, nor do they tie the same harm to each product. Important patient and consumer information about regenerative medicine therapies

A label such as “autologous,” “donor-derived,” or “cord-derived” is not enough to identify the contents, manufacturing controls, or safety evidence. Ask for the product documentation rather than relying on the marketing name. Important patient and consumer information about regenerative medicine therapies

Serious side effects

Serious events include problems that cause death, threaten life, require hospital care, cause lasting disability, or need treatment to prevent permanent harm. This section separates recognized transplant complications from reports involving specific cell products.

Infection and contamination

The pre-treatment for a blood transplant weakens infection defenses sharply. Bacterial, viral, and fungal infections can develop while counts stay low, and donor cells can transmit infections even after donor screening. Ryoncil’s label warns that infections may be passed on because it holds human donor cells and is made with human, pig, and cow-derived ingredients. Stem cell transplant FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display

Germs can enter during collection, processing, storage, or injection. In 2018, the US Centers for Disease Control and Prevention (CDC) investigated infections in 12 patients in three states after contaminated umbilical cord blood-derived products that lacked FDA approval. The infections included bloodstream infections, joint infections, and abscesses around the spine. All 12 patients were hospitalized, and none died. Unopened vials at clinics also contained bacteria. This was a specific outbreak, not an estimate of the risk of every cell product. Mm6750a5.htm

The finding of bacteria in unopened vials illustrates why manufacturing controls matter, not just sterile technique at the injection site. Mm6750a5.htm

Graft-versus-host disease

Graft-versus-host disease, or GVHD, can occur after an allogeneic blood stem cell transplant. Donor white blood cells attack the recipient’s tissues, potentially damaging the skin, liver, intestines, and other organs. GVHD can be acute or chronic and requires specialist follow-up; it is not a general side effect of every treatment described as a stem cell injection. Stem cell transplant

GVHD treatment may involve steroids or other immune-suppressing drugs. Ryoncil is approved in the United States to treat steroid-refractory acute GVHD in children aged 2 months and older, not to prevent GVHD or treat unrelated conditions. Stem cell transplant Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host

Immune reactions and ectopic tissue

Donor cells can trigger immune reactions even with a good match. Your own cells lower some of those risks. They do not remove the risk of swelling at the injection site or a reaction to processing chemicals. Ryoncil’s label warns about allergy-type and sudden infusion reactions, including anaphylaxis, and about ectopic tissue growth — cells growing in the wrong place. FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display

The FDA has received reports of tumor formation after unapproved regenerative products. Those reports do not provide a universal cancer-risk estimate, and they do not mean every cell product causes tumors. A product’s own evidence and follow-up are needed to assess that risk. Important patient and consumer information about regenerative medicine therapies

Organ damage, infertility, and second cancers

For blood stem cell transplants, the NCI lists infertility, cataracts, new second cancers, liver, kidney, lung, or heart damage, plus weak bones and muscles, as possible long-term problems. Your risk depends on the pre-treatment, the donor source, GVHD, past treatment, and your health. They do not attach to every stem cell shot. Stem cell transplant

Neurological and vascular events

In 2026, Japan’s Ministry of Health, Labour and Welfare (MHLW) issued emergency orders after adverse events linked to specific autologous fat-derived MSC plans for chronic pain. In March, one patient’s condition worsened during administration, followed by cardiac arrest and death confirmed at a hospital. The cause remained unknown when officials issued the order. MHLW suspended that specific plan and similar manufacturing during its investigation. Newpage_71555

In April, MHLW reported at least five patients with chills, fever, and nausea after a related chronic-pain plan at a different clinic, with at least one requiring inpatient care. The ministry also identified failures to report and investigate the events. At another institution, one patient developed dizziness, vomiting, and slurred speech and required hospital care for suspected transient ischemic attack, a brief stroke-like event, after receiving a product made through a very similar process. Newpage_72690

These events link to specific products and clinics. They do not define the risk of every stem cell treatment, nor do they prove the cells caused each symptom.

How often do side effects occur?

Ryoncil: The US label reports serious adverse reactions in 35 of 54 treated children (65%). Its table of adverse reactions up to 100 days following treatment lists viral infectious disorders in 56%, bacterial infectious disorders in 44%, infections with an unspecified pathogen in 41%, fever in 35%, hemorrhage in 28%, edema in 22%, abdominal pain and hypertension in 20% each, vomiting in 19%, diarrhea and rash in 17% each, low blood pressure in 15%, and respiratory failure in 11%. Infection categories may overlap and should not be added together. The study had no concurrent control group, and the children were already ill with steroid-refractory acute GVHD after transplant. These are product- and population-specific observations, not a measure of how much harm the product caused or a rate for stem cell therapy overall. FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display

Knee osteoarthritis injections: The Cochrane abstract’s safety analysis reports serious adverse events in 4 of 242 participants receiving stem cell injections and 5 of 219 receiving placebo, across 7 trials with 461 participants at the end of follow-up. The pooled risk ratio was 0.72, with a 95% confidence interval from 0.20 to 2.64. That wide range is compatible with either less or more harm. The evidence was very low certainty, and no withdrawals due to adverse events were reported. These results do not establish that stem cell injections are safer than placebo or settle long-term safety. CD013342_what are benefits and risks stem cell injections knee osteoarthritis

Clinic-sold products: Outbreak reports and emergency orders do not provide an overall incidence rate because they lack a suitable denominator and systematic follow-up. If a clinic quotes 1%, ask for the actual event count, number treated, definition of harm, and follow-up period. One event among 100 patients is 1%; one among 10,000 is 0.01%. Neither percentage is informative without knowing what was measured and whether patients were followed adequately.

Side effects by treatment type

Treat the table as a starting point for a conversation, not a complete consent document.

Treatment What it is Possible adverse effects Serious or delayed risks
Blood stem cell transplant Conditioning chemotherapy, sometimes with radiation, followed by blood-forming stem cells from the patient or a donor; conditioning intensity varies Nausea, vomiting, fatigue, loss of appetite, mouth sores, hair loss, skin reactions, low blood counts Infection, bleeding, GVHD after donor transplant, organ damage, infertility, cataracts, secondary cancers, bone and muscle weakness
Ryoncil (remestemcel-L-rknd) US-approved donor bone marrow MSC product for steroid-refractory acute GVHD in children aged 2 months and older; intravenous infusion Infectious disorders, fever, hemorrhage, edema, abdominal pain, hypertension, vomiting, diarrhea, rash Serious reactions reported in the trial; label warnings include anaphylaxis, transmission of infectious agents, and ectopic tissue formation
Knee osteoarthritis stem cell injection Studied in trials and also marketed by clinics; FDA has not approved regenerative medicine therapies for osteoarthritis Local pain or swelling; reliable product-specific frequencies are often unavailable Joint infection; uncertain serious-harm and long-term safety profile
Clinic-sold “stem cell” infusion or injection Variable products and oversight arrangements; autologous origin alone does not establish safety Collection- or injection-site reactions; inflammatory or immune reactions; frequencies uncertain Reported infections, blindness, tumors, and unintended tissue growth; serious events require product-specific investigation

The table lists possible effects and warnings, not equally common outcomes. A warning about a potential risk is not a measured frequency, and an event reported during treatment is not automatically caused by it. Stem cell transplant FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display CD013342_what are benefits and risks stem cell injections knee osteoarthritis Important patient and consumer information about regenerative medicine therapies

How soon side effects appear

Infusion reactions can occur during or after administration. Transplant-related effects and immune recovery follow a different course. Timing can help a clinician investigate a symptom, but cannot by itself distinguish a reaction from an infection. FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display Stem cell transplant

Period What may occur Important limit
During or after infusion Hypersensitivity or infusion reaction, such as fever, breathing difficulty, or low blood pressure Product-specific; these examples come from the Ryoncil label
Early transplant recovery Nausea, mouth sores, low blood counts, infection, bleeding, and fatigue Often linked to conditioning; severity and duration vary
Months of immune recovery Ongoing vulnerability to infection and a need for monitoring Normal blood counts are not proof of full immune recovery
Long-term follow-up Chronic GVHD, organ damage, infertility, cataracts, or secondary cancers Relevant to blood transplants, not a predicted outcome of every cell injection

The NCI immune-recovery estimates apply to blood stem cell transplants, not knee injections or unapproved IV products. They are not a deadline after which complications become impossible. Stem cell transplant

What raises the risk

  • The cell source. In an allogeneic blood transplant, donor immune cells can attack the recipient’s tissues, causing GVHD; the recipient’s immune system can also reject the graft. Autologous cells avoid donor-recipient mismatch, but not contamination or procedure-related risks.
  • The manufacturing. Cell growth, storage, transport, and safety testing all affect safety. If a clinic cannot name its processing facility or its release checks, you accept an unknown risk.
  • The route and dose. A drip into a vein, a shot into a joint, and a surgically placed implant carry different complications.
  • Your health. An active infection, unstable organ function, bleeding or clotting disorders, a suppressed immune system, pregnancy, a cancer history, and frailty can each shift risk and eligibility.
  • The setting. A transplant hospital with intensive care and 24-hour coverage differs from a clinic that discharges you right after a drip.
  • The follow-up. Ask for a 24-hour emergency number and the name of the doctor who will handle a complication.

Safety planning also includes the risk of delaying effective care. A product that does not work may still cause harm by postponing an established treatment. Important patient and consumer information about regenerative medicine therapies

What approval status tells you about safety

Approval does not itself change a cell’s biological effects. It identifies a product, indication, and regulatory evidence package. A clinical trial tests a defined intervention under a protocol; a commercial offer is not automatically equivalent to that trial. Neither approval nor trial participation guarantees an individual outcome.

Blood stem cell transplant

Blood stem cell transplantation is established care for selected blood cancers, blood disorders, and autoimmune diseases. Eligibility depends on the diagnosis, disease stage, donor options, previous treatment, and ability to tolerate the procedure. Established care can still carry substantial risks. Stem cell transplant

Ryoncil

Ryoncil is the first FDA-approved MSC therapy. It was approved on December 18, 2024, for steroid-refractory acute GVHD in children aged 2 months and older. The approval covers one complication, in one age group, under one dosing plan. It is not an approval for autism, aging, knee pain, tiredness, or general “immune support.” Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host

Ryoncil is a donor bone marrow MSC product given intravenously. The US label contraindicates use in patients with known hypersensitivity to dimethyl sulfoxide (DMSO) or porcine and bovine proteins, and does not recommend it during pregnancy. Its 100-day adverse-reaction table cannot establish all long-term risks. These precautions belong to this product, not every MSC preparation. FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display

Knee osteoarthritis injections

Stem cell injections for knee osteoarthritis are studied in clinical trials and also marketed by clinics. The FDA states that regenerative medicine therapies have not been approved for osteoarthritis or other orthopedic conditions. The Cochrane review found possible small improvements in pain and function, but did not establish their safety or disease-modifying effects. Important patient and consumer information about regenerative medicine therapies CD013342_what are benefits and risks stem cell injections knee osteoarthritis

If offered a knee injection, ask whether the safety study used the same preparation, dose, route, and treatment schedule. A different regulatory setting or a similar cell name does not make two interventions equivalent.

Private clinic infusions

The FDA warns that sellers market unapproved regenerative products for many conditions, including arthritis, chronic pain, and nerve disorders. A listing on ClinicalTrials.gov or an FDA registration never shows that a product is legally marketed or proven to work. Important patient and consumer information about regenerative medicine therapies

Japan has a separate framework for provision of regenerative medicine under a filed provision plan. Filing under that framework is not the same as obtaining product marketing approval, and does not establish efficacy or your personal side-effect risk. Index

What Japan’s rules mean for side-effect risk

Japan’s regenerative medicine law requires providers to file provision plans, report adverse events, and follow manufacturing rules. MHLW can inspect labs and issue emergency orders. Index

Product marketing approval is a separate route involving MHLW approval and PMDA review. The PMDA review-report list covers specific regenerative medical products and indications; it is not approval of every treatment a clinic offers. Check the actual product and approved use rather than assuming that a filed plan or a familiar cell type establishes efficacy or freedom from harm. 0003

Ask for the product name, the approved use, and the PMDA review report — not just the clinic’s registration number. 0003

Warning signs that need urgent care

Seek emergency medical care for severe or rapidly worsening symptoms after treatment, especially:

  • Trouble breathing, chest pain, or fainting.
  • Sudden weakness, trouble speaking, confusion, a seizure, or a severe headache with a stiff neck.
  • New vision loss or sudden changes in vision.
  • Fever with shaking chills, marked weakness, or other signs of serious illness.
  • Redness that spreads fast, severe pain, or severe swelling around an injection site.
  • Bleeding you cannot stop, black stools, or vomiting blood.
  • Yellow eyes or skin, dark urine, or much less urine than usual.

If you have had a blood transplant or have low neutrophils, contact your treatment team’s emergency line immediately for fever or other signs of infection. Do not wait for a high temperature, for the fever to persist, or until the next routine visit. Follow the team’s written fever threshold and emergency instructions. The NCI warns that infections during cancer treatment can be life-threatening and require urgent attention; fever medicines can mask signs of infection, so speak with the team before using them for a fever. Infection

For other new symptoms, such as vomiting that prevents drinking, diarrhea, a rash, or increasing pain, contact your treating clinician promptly. Do not stop prescribed immunosuppressive drugs or antibiotics without medical advice. If you cannot reach the team and feel seriously unwell, seek emergency care.

If you think an unapproved product harmed you, tell the regulator as well as the clinic. In the US, contact FDA MedWatch. In Japan, MHLW operates a reporting desk for regenerative medicine safety concerns. Important patient and consumer information about regenerative medicine therapies Index

Side-effect questions to ask before you agree

Ask for written answers about side effects:

  1. What exactly is being given? Cell type, source (your own, donor, cord blood, amniotic, or other), and whether the cells are lab-grown or minimally processed.
  2. What is the regulatory status? Is this product approved for my condition, part of a registered trial, offered under a provision plan, or sold as a private service?
  3. What human evidence exists in people like me? Diagnosis, stage, age, cell type, dose, route, comparison group, patient count, endpoints, and follow-up.
  4. What were the serious harms? How many, what kind, how were they managed, and what happened to those patients?
  5. Who processed the cells? Facility name, release tests, contamination controls, and what happens if a batch fails.
  6. Who handles complications? Emergency contact, hospital admitting rights, intensive care access, and who pays.
  7. What is the follow-up plan? Visits, scans, blood tests, and the duration of monitoring.
  8. What standard treatment would I delay or stop? Ask about the effects of waiting.
  9. What is the full cost, including complications? Procedure, processing, follow-up, travel, and hospitalization.
  10. Can I see the consent form and the published study? Review both before paying.

Applying the evidence to a treatment offer

If you are considering a knee injection and are shown Ryoncil’s approval, check the indication: its approval concerns a pediatric transplant complication, not knee osteoarthritis. Its safety percentages describe those ill children, not your proposed joint injection. This is a concrete reason to ask for evidence matching your condition and the exact product. Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host FdaDrugXsl.cfm?setid=a4e0918f 7444 4694 adeb d38d98345659&type=display

If an offer says “no serious side effects,” ask whether that means no events were recorded, no events were judged treatment-related, or no follow-up data were collected. Request both the number treated and the number reached at follow-up. If a serious-harm rate is unknown, it should be described as unknown rather than zero.

What to do if a side effect appears

During a drip, tell staff at once if you feel short of breath, faint, chilly, itchy, or nauseated. Staff can stop the drip and treat the reaction. Do not stay silent until the bag empties from fear of “wasting” the treatment.

At home, record the treatment date, product name, symptom onset, temperature, and whether symptoms are worsening. Keep the treatment and discharge documents available for an emergency clinician. Photographs of a rash or swelling may help, but do not delay urgent care to collect them. If traveling, arrange a local emergency plan and discharge notes you can understand before leaving the clinic.

Considering a consultation in Japan? Ask which treatment documents and follow-up arrangements are available before deciding. For urgent symptoms, contact your treating team or emergency services, not an inquiry form.

Ask About Consultation Arrangements

The bottom line

The most useful side-effect list is the one for your exact treatment. For a blood transplant, discuss conditioning effects, infection, GVHD, and long-term organ and fertility risks. For a cell injection, ask for product-specific human safety data, the limits of follow-up, and a complication plan. An unknown risk is not the same as no risk.

This article provides general education only. It does not replace advice from a doctor who knows your health history.

Sources

Sources were accessed on 24 October 2026. The NCI transplant page, FDA consumer warning, Ryoncil label, and Cochrane review were rechecked on 27 October 2026; the NCI infection page was accessed on that date. The MHLW emergency orders describe findings at the time they were issued, not a later determination of causation. English descriptions of Japanese sources are paraphrases, not official translations.

  1. National Cancer Institute (NCI), National Institutes of Health, United States. Stem Cell Transplants in Cancer Treatment. Updated 5 October 2023. https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant
  2. US Food and Drug Administration (FDA). Important Patient and Consumer Information About Regenerative Medicine Therapies. 3 June 2021; content current as of 8 April 2024. https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies
  3. US Food and Drug Administration (FDA). FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease. 18 December 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host
  4. Mesoblast, Inc.; US prescribing information via DailyMed (National Library of Medicine). Ryoncil (remestemcel-L-rknd) suspension for intravenous infusion: full prescribing information. Revised September 2025. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a4e0918f-7444-4694-adeb-d38d98345659&type=display
  5. Cochrane Collaboration. What are the benefits and risks of stem cell injections for knee osteoarthritis? Published 2 April 2025; evidence up to 15 September 2023. https://www.cochrane.org/evidence/CD013342_what-are-benefits-and-risks-stem-cell-injections-knee-osteoarthritis
  6. US Centers for Disease Control and Prevention (CDC), Morbidity and Mortality Weekly Report. Notes from the Field: Infections After Receipt of Bacterially Contaminated Umbilical Cord Blood–Derived Stem Cell Products for Other Than Hematopoietic or Immunologic Reconstitution — United States, 2018. 21 December 2018. https://www.cdc.gov/mmwr/volumes/67/wr/mm6750a5.htm
  7. Ministry of Health, Labour and Welfare (MHLW), Japan. Emergency order under the Act on the Safety of Regenerative Medicine. 13 March 2026; Japanese-language release. https://www.mhlw.go.jp/stf/newpage_71555.html
  8. Ministry of Health, Labour and Welfare (MHLW), Japan. Emergency order under the Act on the Safety of Regenerative Medicine. 21 April 2026; Japanese-language release. https://www.mhlw.go.jp/stf/newpage_72690.html
  9. Ministry of Health, Labour and Welfare (MHLW), Japan. Regenerative and cell medicine and gene therapy. Japanese-language regulatory portal; accessed 24 October 2026. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/saisei_iryou/index.html
  10. Pharmaceuticals and Medical Devices Agency (PMDA), Japan. Review Reports: Regenerative Medical Products. Accessed 24 October 2026. https://www.pmda.go.jp/english/review-services/reviews/approved-information/0003.html
  11. National Cancer Institute, National Institutes of Health, United States. Infection and Neutropenia during Cancer Treatment. Reviewed 23 January 2020; accessed 27 October 2026. https://www.cancer.gov/about-cancer/treatment/side-effects/infection